Acute Respiratory Infection, Influenza
Conditions
Keywords
influenza, acute respiratory viral infection, grippe, prevention
Brief summary
Influenza and other acute respiratory viral infections remain practically uncontrollable diseases due to the high variability of the antigenic structure of influenza viruses and the heterogeneity of pathogens of acute respiratory infections. Therefore, for the prevention and treatment of influenza, acute respiratory viral infections and herpes infections, it is relevant to develop drugs - immunomodulators that mobilize the reserves of nonspecific and specific immune systems and enhance the effects of these systems against the pathogens. The drug CYCLOFERON, 150 mg, enteric-coated tablets, contains the active substance meglumine acridone acetate, which is an interferon inducer. Interferons are the most important system of innate immunity, which has antiviral and immunomodulatory effects, and can protect the body from infection with a virus, and in case of infection, fight the causative agent of the disease. The planned clinical trial of the efficacy and safety of the drug CYCLOFERON in the dosage form of a tablet will study its ability to prevent influenza and other respiratory viral infections in adults who have already had close contact with patients with manifest disease.
Interventions
DRUGCycloferon
Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.
DRUGPlacebo
Placebo tablets, 4 tablets per day on days 1, 2, 4, 6 and 8
Sponsors
POLYSAN Scientific & Technological Pharmaceutical Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Randomization is performed using the Internet Interactive Response System (IWRS) before the start of the drug dosing period. During the randomization procedure, the investigator, after assessing whether the subject meets the inclusion criteria and the absence of non-inclusion criteria, will contact IWRS, the system will record the fact that the subject has been randomized and will automatically report the package number of the drug that must be given to the subject. The study drug CYCLOFERON®, enteric-coated tablets, 150 mg (NTFF POLYSAN LLC, Russia), is supplied in the form of enteric-coated tablets, 150 mg. 10 tablets in a blister pack, 5 blister packs in a cardboard box. The reference drug PLACEBO, enteric-coated tablets, 150 mg (NTFF POLYSAN LLC, Russia), is supplied in the form of enteric-coated tablets, 150 mg. 10 tablets in a blister pack, 5 blister packs in a cardboard box.
Intervention model description
Double-blind, placebo-controlled, randomized, two-parallel group comparative study
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Male and female subjects aged 18 to 65 years inclusive. 2. Written informed consent. 3. Co-living with persons who has developed influenza or other acute respiratory viral infection, diagnosed no more than 3 days ago. 4. No signs of acute respiratory viral infection, influenza or COVID-19 at the time of inclusion in the study. 5. For women with preserved reproductive potential - a negative pregnancy test and consent to use approved methods of contraception during the entire period of participation in the study; for men - consent to use approved methods of contraception during the entire period of participation in the study and for 3 weeks after the end of the study.
Exclusion criteria
1. Known or suspected hypersensitivity to meglumine acridone acetate and/or any other component of the drug/placebo. 2. Lactose intolerance 3. Diseases of the digestive system in the acute stage (erosions, gastric and/or duodenal ulcers, gastritis and duodenitis). 4. History of allergic reactions. 5. Decompensated liver cirrhosis. 6. Diseases of the thyroid gland. 7. Congenital or acquired immunodeficiency. 8. Signs of acute respiratory viral infection, influenza or COVID-19 at the time of inclusion. 9. Positive result of a rapid test for the presence of SARS-CoV-2 at the time of screening. 10. Vaccination to prevent COVID-19 and/or influenza within 6 months before screening, planned vaccination during a clinical trial. 11. History of positive test result for HIV types 1 or 2. 12. Pregnancy or breastfeeding period (for women). 13. Alcoholism, drug addiction, substance and/or drug abuse in history and/or at the time of screening. 14. Participation in another clinical trial within 3 months before inclusion. 15. Subject is already receiving cycloferon. 16. Subject is receiving prohibited therapy or was receiving it within 30 days prior to screening. 17. Failure to observe the subject during the study period. 18. Other reasons that, in the opinion of the researcher, prevent the subject from participating in the study or create an unreasonable risk (for example, a history of autoimmune diseases, etc.).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of influenza/other acute respiratory viral infection in the study groups | 14 days | the proportion of subjects with clinically manifest and laboratory confirmed influenza or other acute respiratory viral infection, developed within days 1-14 of the study. |
Countries
Russia
Outcome results
None listed